ENLIVEN THERAPEUTICS, INC.
ELVNLoading price...
Overview
Previous Close35.53
Open35.66
Ask39.91
Bid38.23
Day's Range35.66 - 40.58
52 Week Range13.30 - 40.58
PE Ratio(TTM)--
Market Cap2.35B
Volume3.38M
Avg. Volume1.1M
12 Months Earnings-103.69M
12 Months Revenue0.00
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 119.66M | 119.66M | 104.55M | 83.53M | 38.79M |
| Profit after Tax (Net Income) | -103.69M | -103.69M | -89.02M | -71.58M | -37.66M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Boulder, United States
Website: https://www.enliventherapeutics.com
Co-Founder & Head of Pipeline: Mr. Samuel S. Kintz M.B.A.
Employees: 60
About Company:
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.